Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer.

Yamada S1, Tsuyoshi H1, Tsujikawa T2, Okazawa H2, Yoshida Y1.

Author information

1

From the Department of Obstetrics and Gynecology, Faculty of Medical Sciences, and.

2

Biomedical Imaging Research Center, University of Fukui, Fukui, Japan.

Abstract

For early-stage endometrial cancer patients who wish to preserve fertility, progestin treatment is effective. However, repeated endometrial curettage to evaluate treatment response may cause infertility. The clinical courses of 3 patients who were treated with fertility-sparing progestin treatment and underwent serial F-FES PET before and after treatment are presented. The SUVmean decreased greatly in patients with pathologically complete response (44.2%, 46.2%), whereas there was only a small change (22.5%) in the patient with pathologically stable disease who finally underwent hysterectomy. F-FES PET can be a noninvasive method to evaluate response to fertility-sparing progestin treatment.

PMID:

 

31107747

 

DOI:

 

10.1097/RLU.0000000000002612

Similar articles